HansBiomed Corporation Total Liabilities
HansBiomed Corporation total liabilities. Based on the latest financial reports, HansBiomed Corporation (042520) has total liabilities worth ₩92.52 Billion KRW (≈ $62.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of HansBiomed Corporation to evaluate the company's liquid asset resilience ratio.
Total Liabilities of HansBiomed Corporation (2012–2025)
Total liabilities of HansBiomed Corporation from 2012 to 2025. This chart illustrates how HansBiomed Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore HansBiomed Corporation strategic investment ratio to see how much of total assets are deployed in long-term investments.
HansBiomed Corporation Competitors by Total Liabilities
The table below lists competitors of HansBiomed Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
United Utilities Group PLC
LSE:UU
|
UK | GBX15.89 Billion |
|
Ampco-Pittsburgh Corporation
NYSE:AP
|
USA | $449.63 Million |
|
Mnc Land Tbk
JK:KPIG
|
Indonesia | Rp7.31 Trillion |
|
Beijing Tongtech Co Ltd
SHE:300379
|
China | CN¥342.06 Million |
|
Multitude SE
LSE:0R4W
|
UK | €1.31 Billion |
|
NSE SA
PA:ALNSE
|
France | €53.41 Million |
|
LBS Bina Group Bhd
KLSE:5789
|
Malaysia | RM2.52 Billion |
|
Bank Agris Tbk
JK:AGRS
|
Indonesia | Rp16.70 Trillion |
Liability Composition Analysis (2012–2025)
This chart breaks down HansBiomed Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 042520 total assets.
Liquidity & Leverage Metrics
HansBiomed Corporation Total Liabilities Ratios Explained
HansBiomed Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HansBiomed Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HansBiomed Corporation (2012–2025)
The table below shows the annual total liabilities of HansBiomed Corporation from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | ₩92.52 Billion ≈ $62.70 Million |
+69.47% |
| 2024-09-30 | ₩54.59 Billion ≈ $37.00 Million |
-24.62% |
| 2023-09-30 | ₩72.42 Billion ≈ $49.08 Million |
-15.84% |
| 2022-09-30 | ₩86.05 Billion ≈ $58.32 Million |
+1.25% |
| 2021-09-30 | ₩84.99 Billion ≈ $57.60 Million |
+18.92% |
| 2020-09-30 | ₩71.47 Billion ≈ $48.43 Million |
+42.87% |
| 2019-09-30 | ₩50.03 Billion ≈ $33.90 Million |
+88.82% |
| 2018-09-30 | ₩26.49 Billion ≈ $17.95 Million |
+0.12% |
| 2017-09-30 | ₩26.46 Billion ≈ $17.93 Million |
+47.83% |
| 2016-09-30 | ₩17.90 Billion ≈ $12.13 Million |
+99.90% |
| 2015-09-30 | ₩8.95 Billion ≈ $6.07 Million |
+80.81% |
| 2014-09-30 | ₩4.95 Billion ≈ $3.36 Million |
+22.19% |
| 2013-09-30 | ₩4.05 Billion ≈ $2.75 Million |
+34.55% |
| 2012-09-30 | ₩3.01 Billion ≈ $2.04 Million |
-- |
About HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more